Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2974
Title: | Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial | Authors: | McCallum, G. B. Fong, S. M. Grimwood, K. Nathan, A. M. Byrnes, C. A. Ooi, M. H. Nachiappan, N. Saari, N. Morris, P. S. Yeo, T. W. Ware, R. S. Elogius, B. W. Oguoma, V. M. Yerkovich, S. T. De Bruyne, J. Lawrence, K. A. Lee, B. Upham, J. W. Torzillo, P. J. Chang, Anne |
Issue Date: | 2022 | Source: | 41, (7), 2022, p. 549-555 | Pages: | 549-555 | Journal: | Pediatric Infectious Disease Journal | Abstract: | Background: High-level evidence is limited for antibiotic duration in children hospitalized with community-acquired pneumonia (CAP) from First Nations and other at-risk populations of chronic respiratory disorders. As part of a larger study, we determined whether an extended antibiotic course is superior to a standard course for achieving clinical cure at 4 weeks in children 3 months to ≤5 years old hospitalized with CAP. Methods: In our multinational (Australia, New Zealand, Malaysia), double-blind, superiority randomized controlled trial, children hospitalized with uncomplicated, radiographic-confirmed, CAP received 1-3 days of intravenous antibiotics followed by 3 days of oral amoxicillin-clavulanate (80 mg/kg, amoxicillin component, divided twice daily) and then randomized to extended (13-14 days duration) or standard (5-6 days) antibiotics. The primary outcome was clinical cure (complete resolution of respiratory symptoms/signs) 4 weeks postenrollment. Secondary outcomes included adverse events, nasopharyngeal bacterial pathogens and antimicrobial resistance at 4 weeks. Results: Of 372 children enrolled, 324 fulfilled the inclusion criteria and were randomized. Using intention-to-treat analysis, between-group clinical cure rates were similar (extended course: n = 127/163, 77.9%; standard course: n = 131/161, 81.3%; relative risk = 0.96, 95% confidence interval = 0.86-1.07). There were no significant between-group differences for adverse events (extended course: n = 43/163, 26.4%; standard course, n = 32/161, 19.9%) or nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus or antimicrobial resistance. Conclusions: Among children hospitalized with pneumonia and at-risk of chronic respiratory illnesses, an extended antibiotic course was not superior to a standard course at achieving clinical cure at 4 weeks. Additional research will identify if an extended course provides longer-term benefits.L20188099782022-06-28 | DOI: | 10.1097/INF.0000000000003558 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2018809978&from=exporthttp://dx.doi.org/10.1097/INF.0000000000003558 | | Keywords: | Staphylococcus aureus;Streptococcus pneumoniae;Moraxella catarrhalis;vomiting;treatment duration;amoxicillinamoxicillin plus clavulanic acid;ampicillin;antibiotic agent;cefotaxime;ceftriaxone;cefuroxime;cloxacillin;penicillin G;antibiotic resistance;antibiotic therapy;article;child;community acquired pneumonia;controlled study;diarrhea;double blind procedure;female;Haemophilus influenzae;hospital readmission;hospitalization;human;intention to treat analysis;major clinical study;male;multicenter study;nausea;outcome assessment;parallel design;preschool child;randomized controlled trial;rash;risk factor | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.